Novel Therapeutics in the Treatment and Management of Multiple Myeloma at ASH 2017
WebcastFaculty
OVERVIEW
Novel Therapeutics in the Treatment and Management of Multiple Myeloma at ASH 2017 is organized by Academic CME and will be held during Feb 15, 2018 - Feb 14, 2019.
The target audience for this medical event is Hematologists/oncologists, internists, nurse practitioners, nurses and other healthcare providers responsible for the management of patients with multiple myeloma. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Course Description:
This CME/CNE program will discuss recent advances in the treatment and management of multiple myeloma (MM) as presented at the American Society of Hematology 59th Annual Meeting & Exposition in Atlanta, Georgia. The expert faculty panel will provide learners with a scientific update regarding kidney toxicity, fractures, and other skeletal-related events as they relate to MM patient care. Recent clinical trial data, particularly that pertaining to newly diagnosed patients, relapse refractory multiple myeloma and supportive care, will be analyzed and clinical relevance discussed. The expert faculty will review optimal means of incorporating newer therapies in practice utilizing a team-based approach to improve outcomes and quality of life in multiple myeloma patients. At the conclusion of this educational activity, learners will be better acquainted with optimal treatment, monitoring, and management techniques for patients with MM.
Conference Objectives:
• Discuss the comorbidities of multiple myeloma, including kidney toxicity, fractures, and other skeletal-related events
• Analyze clinical trial data related to the treatment of multiple myeloma as presented at ASH 2017
• Incorporate newer therapies to improve outcomes and quality of life in patients with multiple myeloma using a team-based approach
Additional details will be posted as soon as they are available.
The target audience for this medical event is Hematologists/oncologists, internists, nurse practitioners, nurses and other healthcare providers responsible for the management of patients with multiple myeloma. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Course Description:
This CME/CNE program will discuss recent advances in the treatment and management of multiple myeloma (MM) as presented at the American Society of Hematology 59th Annual Meeting & Exposition in Atlanta, Georgia. The expert faculty panel will provide learners with a scientific update regarding kidney toxicity, fractures, and other skeletal-related events as they relate to MM patient care. Recent clinical trial data, particularly that pertaining to newly diagnosed patients, relapse refractory multiple myeloma and supportive care, will be analyzed and clinical relevance discussed. The expert faculty will review optimal means of incorporating newer therapies in practice utilizing a team-based approach to improve outcomes and quality of life in multiple myeloma patients. At the conclusion of this educational activity, learners will be better acquainted with optimal treatment, monitoring, and management techniques for patients with MM.
Conference Objectives:
• Discuss the comorbidities of multiple myeloma, including kidney toxicity, fractures, and other skeletal-related events
• Analyze clinical trial data related to the treatment of multiple myeloma as presented at ASH 2017
• Incorporate newer therapies to improve outcomes and quality of life in patients with multiple myeloma using a team-based approach
Additional details will be posted as soon as they are available.
SPECIALITIES
Hematology Blood and Marrow TransplantOncology
Quick Links